(Adds detail on EMA recommendations)
Nov 11 (Reuters) - Europe's drug regulator on Thursday
recommended approving two COVID-19 therapies based on monoclonal
antibodies, one developed by U.S. biotech firm Regeneron
REGN.O and Swiss giant Roche ROG.S and another from South
Korea's Celltrion 091990.KQ .
The approval was imminent amid a spike in coronavirus
infections, Reuters had reported earlier this week, and marks
the first approval for any COVID-19 treatment in the continent
after Gilead's GILD.O remdesivir last year https://www.reuters.com/article/us-health-coronavirus-gilead-europe-idUSKBN23W1ZH.
urn:newsml:reuters.com:*:nL1N2S00ZV
Regeneron-Roche's antibody cocktail, Ronapreve, has been
backed https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
by the human medicines committee of the European Medicines
Agency (EMA) for treating adults and adolescents who do not
require oxygen support and are at high risk of severe disease.
Celltrion's Regkirona, however, has been recommended only
for adults with similar conditions.
While the evaluation of formal applications for authorising
the medicines is under way, the two drugs are already available
to some patients in the European Union as the EMA assisted
member states on early use in some cases.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun
Koyyur)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793 ;))